Abstract. Human malignant melanoma is notoriously resistant to pharmacological modulation. We describe here for the first time that the synthetic retinoid CD437 has a strong dose-dependent antiproliferative effect on human melanoma cells (IC50:5 × 10-6 M) via the induction of programmed cell death, as judged by analysis of cell morphology, electron microscopical features, and DNA fragmentation. Programmed cell death was preceded by a strong activation of the AP-1 complex in CD437-treated cells as demonstrated by gel retardation and chloramphenicol transferase (CAT) assays. Northern blot analysis showed a time-dependent increase in
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"r~ETINOIOS, structural analogs of vitamin A, are in-~-~ volved in a wide range of biologicaI processes in-.It. ~ cluding cell differentiation, morphogenesis, and proliferation (for reviews see Kastner et al., 1995; Mangelsdorf and Evans, 1995) . These parameters have been analyzed in various murine and human cancer cell lines including melanoma for more than fifteen years (Lotan, 1980; Meyskens and Fuller, 1980; Hoal et al., 1982) . Although their clinical usefulness has so far been limited by various adverse effects, retinoids are of increasing importance for the development of oncological strategies because of their antineoplastic activity (for reviews see Bollag and Holdener, 1992; Smith et al., 1992; Kurie et al., 1994) . These may be mediated either directly by toxic membrane damage or by activation of oxidative processes or indirectly by induction of tumor suppressive mediators or by modulation of receptors necessary for growth factor inter-action or immune recognition (Evans, 1988; Apfel et al., I991; Mangelsdorf and Evans, 1995) . At the molecular level it is known that retinoids bind to and activate specific nuclear receptors, the retinoic acid receptors (RARs) 1 and retinoid X receptors (RXRs), which in turn, as homo-or heterodimers, recognize specific DNA sequences regulating target gene expression (for reviews see Apfel et al., 1991; Kastner et al., 1995; Mangelsdorf and Evans, 1995) . Recently, it has been shown that retinoids interfere with other transcription factors, particularly AP-1, which is formed by members of the Fos and Jun protein family (Schtile et al., 1990 (Schtile et al., , 1991 Yang-Yen et al., 1991; Pfahl, 1993) . AP-1 inhibition leads to antiproliferative effects in tumor cells independent of the receptor-transactivating potential of the retinoids (Fanjul et al., 1994; J.-Y. Chen et al., 1995; Li et al., 1996) .
In humans, retinoids have so far not been used successfully for the treatment of malignant melanoma (Ho and Sober, 1990; Lotan et al., 1991) . Only recently, a RAR-~t-selective synthetic retinoid CD437 has been identified (Bernard et al., 1992 ) that strongly inhibited in vitro cell proliferation of various human melanoma cell lines in a close-dependent manner (Schadendorf et al., 1994) . Since malignant melanoma cells are notoriously resistant to chemotherapeutic drugs in vitro and in vivo (Ho and Sober, 1990; Schadendorf et al., 1995) and new strategies for the treatment of metastatic melanoma are urgently needed, we used the human melanoma cell line MeWo as a model system for studying the mechanism involved in CD437-induced growth inhibition in greater detail. CD437 is shown to be capable of inducing the transcription factor AP-1 on mRNA and protein levels leading eventually to programmed cell death of MeWo ceils in vitro. Furthermore, treatment with CD437 markedly reduced the growth of human melanoma cells in nude mice.
Materials and Methods

Cell Culture andExposure to Retinoids
Human melanoma cells (MeWo, were grown in RPMI 1640 medium (GIBCO BRL, Eggenstein, Germany) supplemented with charcoal-treated 10% FCS (Schadendorf et al., 1993) . For retinoid treatment, the same medium was used. The medium and retinoids were changed every 3 d. The retinoids all-trans-retinoic acid (RA), CD437, and CD2398 were used. CD437 is known to activate RAR-'¢ with high selectivity, whereas CD2398, which is structurally highly homologous to CD437, has no binding affinity to any known retinoid receptor. RA binds to all RAR subtypes with high affinity hut not to RXR receptors (Bernard et al., 1992; Schadendorf et al., 1994) . All retinoids were kindly provided by Drs. B. Shroot and U. Reichert (CIRD, Galderma, Valbonne, France) and were dissolved in DMSO. The final concentration in all cultures was 0.1% DMSO.
Electrophoretic Mobility Shift Assay
5 × 106 cells were stimulated with RA, CD437, and CD2398 (10 -5 M) for the times indicated. Cell extracts were prepared as described previously (Trede et al., 1991; Pahl and Baeuerle, 1995) . Total cell extracts were prepared using high-salt detergent buffer (Totex; 20 mM Hepes, pH 7.9, 350 mM NaCl, 20% [wt/vol} glycerol, 1% [wt/vol] NP-40, 5 mM MgClz, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM DTr, 0.1% PMSF, and 1% aprotinin). Cells were harvested by centrifugation and washed once in ice-cold PBS and resuspended in 4 vol of Totex buffer. The cell lysate was incubated on ice for 30 rain and then centrifuged for 5 rain at 13,000 g at 4°C. The protein content of the supernatant was determined, and equal amounts of protein (10-20 p~g) were added to a reaction mixture containing 20 ~g BSA (Sigma Chemical Co., St. Louis, MO), 2 p,g poly(di-dC) (dldC purchased from Pharmacia LKB Biotechnology, Piscataway, NJ), 2 ~I buffer D+ (20 mM Hepes, pH 7.9, 20% glycerine, 100 mM KCI, 0.5 mM EDTA, 0.25% NP-40, 2 mM DTT, 0.1% PMSF), 4 In,1 buffer F (20% Ficoll 400, 100 mM Hepes, 300 mM KCL, 10 mM DTT, 0.1% PMSF), and 100,000 cpm of et-32p-labeled oligonucleotide in a final volume of 20 I~l-Samples were incubated at room temperature for 25 rain. For the supershift assays, 2.5 ILl of antibody were added to the reaction simultaneously with the protein and incubated as described. The following antibodies were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA): 4-10G (mouse IgG2~; broadly reactive with c-Fos, Fos B, Fra-1, and Fra-2), 4 (rabbit polyclonal IgG; reactive with c- ATF-1), C-19 (rabbit polyclonal IgG; reactive with ATF-2), C-19 (rabbit polyclonal IgG; reactive with ATF-3), and Z5 (mouse monoclonal IgG~; reactive with ATF-4). AP-1 oligonucleotide (Promega Corp., Madison, WI) was labeled using [3,-32p]ATP (3,000 Ci/ml; Amersham Corp., Arlington Heights, IL) and T4 polynucleotide kinase (Promega Corp.).
DNA Transfection and CAT Assay
Cells were DNA transfected using cationic liposomes (Lipofectin; Life Technology, Inc., Eggenstein, FRG) under serum-free conditions as described previously . For the transfection assay, ceils were seeded into 6-well plates at a density of 12,000 cells/era 2. Cultures were transfected 1 d after they reached 50--60% confluency, and cells were incubated with DNA-liposome complexes (2 p,g DNA per well) for 24 h. To exclude differences in transfection efficiency, cotransfection of a cytomegalovirus-driven [3-galactosidase construct (Stratagene, Heidelberg, Germany) was performed in each experiment (1 p,g per well). 48 h after transfection, cells were washed twice with PBS and harvested. After centrifugation, the pellet was resuspended in 0.125 M Tris HC1 buffer, pH 7.8, and lysed by repeated cycles of freezing and thawing at -80°C, and the total protein concentration of the cell lysates was determined. To determine AP-l-dependent CAT activities, a DNA fragment containing five AP-1 DNA-binding sites was generated by PCR (primer: ACTgAATCAACTgAATCAACTgAATCAACTgAATCAACTgAATCATT) cloned into the BgllI site of the pCAT-promoter vector (Promega Corp.), and the resulting plasmid was transfected into MeWo cells. CAT activity was measured as described previously Ntirnberg et al., 1995) . Commercially available CAT was used as a standard for the determination of enzyme activity in extracts of transfected cells. Transfection efficiency was estimated by cotransfection of a !3-galactosidase plasmid in each experiment.
Northern Blot Analysis and In Situ Hybridization
RNA was isolated using an RNeasy Total RNA Kit (QIAGEN Inc., Chatsworth, CA), electrophoresed through 1% agarose-formaldehyde gels, and then transferred to nylon membranes (Boehringer Mannheim Corp.). Northern blot hybridization to random-primed 32p-labeled DNAs and high stringency washes were performed as described (Sambrook et al., 1989) . Signals were visualized by autoradiography. The eDNA probes for c-los, c-jun (Ntirnberg et al., 1995) , and p53 (Baker et al., 1990) were excised from their plasmid vectors and random-primed with [ot-32P]dCTP (3,000 Ci/mmol; Du Pont-New England Nuclear, Boston, MA). For in situ hybridization, digoxigenin-labeled antisense and sense c-los riboprobes were synthezised using T7 and SP6 RNA polymerase (DIG-RNA labeling kit; Boehringer Mannheim Corp.). The hybridization procedure of paraffin-embedded sections of cutaneous tumors followed a standard protocol using a colorimetric detection system (Ntirnberg et al., 1995) .
Electron Microscopy
The method used has been described in detail elsewhere (Kolde and Knop, 1986) . Briefly, the cells were fixed in half-strength Karnovsky sola- tion (0.1 M cacodylate buffer, pH 7.4) for 30 min at 4°C. After washing in PBS, the cells were postfixed in 1.33% osmic acid (0.05 M phosphate buffer, pH 7.4) for 30 min, dehydrated in a graded ethanol series, and embedded in Araldite using beam capsules. Ultrathin sections were stained with uranyl acetate and lead citrate and examined with an electron microscope (model 9S; Carl Zeiss, Inc., Thornwood, NY). Necrotic and apoptotic cell figures were counted and expressed by a semiquantitative scoring system as follows: 0, no cell with altered morphology; + / -single cells (up to 3%); +, few cells (between 3-10%); + +, moderate number of cells (11-50%); + + +, numerous cells (>50%).
Melanoma Nude Mouse Model
For the in vivo experiments, male Swiss-nu/nu mice (Bomholtgaard; Ry, Denmark) weighing 20-25 g were used. Mice were kept under sterile conditions at 24-26°C room temperature, 50% relative humidity, and 12 h light-dark rhythm in laminar flow shelves and were supplied with autoclaved food (Sniff; Soest, Germany) and bedding. The drinking water was filtered and acidified (pH 4.0). For treatment of melanoma xenografts, previously established MeWo melanoma tumors of 1-2 mm in diameter were implanted into the right flank of animals. After tumor growth for 10 d, groups of mice (n = 8) were either treated with saline p.o. or were injected intratumorally for 3 wk or were fed with various concentrations of CD437 (10 mg/kg/body weight and 30 mg/kg/body weight). In addition, tumors of a fifth group were injected with CD437 (10 mg/kg/body weight) each day. Mice were visited daily and growing tumors were measured twice weekly with a caliperlike instrument. No signs of major toxicity were observed, as judged by loss of body weight over the treatment period. CD437-treated animals showed, however, some scaling of the skin, which is typical for retinoid treatment.
Results
CD437 Induces Programmed Cell Death In Vitro
CD437 is a new aromatic retinoid that causes selective RAR-~/activation (Bernard et aI., 1992) and that has recently been shown to induce apoptosis in human breast cancer cells (Shao et al., t995) . We tested CD437 for its antiproliferative effects on different human melanoma cell lines (MeWo, MV3, and SK-Mel-23) in comparison to the structurally closely related compound CD2398, which does not bind to any known retinoid receptor (Bernard et al., 1992; Schadendorf et al., 1994) , and RA (Fig. 1) . Treatment for 72 h with CD437 caused a strong dose-dependent growth inhibition in all melanoma cell lines (Fig. 2 A) . At a concentration of 5 × 10 -6 M CD437, only about 5-25% of the cells remained viable after 3 d. The concentrations of CD437 required for 50% growth inhibition (I(250) ranged from 10 -6 M for MeWo to 10 -7 M for SK-Mel-23 showing the highest sensitivity. In contrast, proliferation of all cell lines was not affected in the presence of RA (10-s-10 -s M) (data not shown). Using MeWo melanoma cells, we studied the effect of retinoids in more detail. In Fig. 2 B, the effect of CD437, RA, and CD2398 on MeWo cell growth is shown. CD437 in the range of 10-6-t0 -5 M strongly inhibited cell growth. In contrast, CD2398 had a moderate inhibitory effect only at the highest concentration tested (10 -5 M), and RA-treated cultures retained normal ceil growth. As shown in Fig. 2 C, the CD437-induced growth inhibition is time dependent; again, RA did not affect cell proliferation, and treatment with CD2398 (10 -5 M) resulted in an ~30% reduction in the number of viable ceils after prolonged exposure (72 h). At present, the mechanism of the reduced growth inhibitory effect of CD2398 is completely unknown and might be due to interaction of the hydrophobic retinoid with membranes or, since CD2398 does not bind to receptors of the RAR and RXR family (Bernard et al., 1992) , activation of a yet unknown receptor. To test whether the effect of CD437 is reversible or irreversible, MeWo cells were treated with CD437 for different time periods (6, 12, 24, 36 , and 48 h) followed by a 72-h regeneration period. As outlined in Fig. 2 D , the antiproliferative effect could be partially reversed after short-time exposure to CD437 for 6 or 12 h, respectively, with a recovery of around 45-55% of viable cells after the regeneration period compared to controls. In contrast, prolonged CD437 exposure (24--48 h) resulted in an irreversible growth inhibition (Fig. 2 D) . Furthermore, MeWo cells were sensitive to phorbol esterinduced growth inhibition up to 40% at PMA concentrations ranging from 10--100 ng/ml (data not shown). The same results were obtained with MV3 cells, whereas SKMel-23 cells did not respond to PMA treatment under the conditions tested (data not shown).
In comparison to untreated cells, the cell morphology of CD437-treated MeWo cells was changed dramatically (not shown), suggesting the possible induction of programmed cell death. To test this hypothesis, histone-associated DNA fragments (nucleosomes) in the cytoplasmatic fraction of MeWo cells treated with the three compounds over a concentration range from 10 -8 M to 10 .5 M were quantified by a cell death detection ELISA. As shown in Fig. 3 , RA had no effect and CD2398 caused a 5-7-fold increase of histone-associated DNA fragments only at the highest concentrations tested (10 -s M). A dramatic increase in DNA fragmentation (6-12-fold) could be observed in CD437-treated cells over a concentration range from 10 .6 M to 10 -5 M. In agreement with these findings, electron microscopy revealed regularly structured cells in untreated (Fig.  4 A) or RA-treated preparations, whereas various amounts of apoptotic and necrotic melanoma cells were detectable in CD437-treated groups (Fig. 4, B and C) . After administration of compound CD437, there were numerous apoptotic melanoma cells and a few cells with necrotic alterations, while in the controls, no necrotic and only few if any apoptotic cells were found. Apoptotic MeWo cells were characterized by segregation of compacted chromatin, condensation of cytoplasm and organelles, intact membranes, and fragmentation of the cell (Fig. 4 B) . In contrast, the rare necrotic cells demonstrated swelling of the cytoplasm and mitochondria, edematous nuclei with clumped chromatin, and dissolution of membranes (Fig. 4  C) . The relative numbers of apoptotic and necrotic melanoma cells were assessed by a semiquantitative ultrastructural analysis, as summarized in Table I . Whereas necrotic cells were not detectable in control cells or cells exposed to CD2398 or RA, CD437-treated cells exhibited few cells (up to 10%); however, cells were found to undergo apoptotic death in more than 75% upon exposure. Apoptotic ceils were also found in up to 10% of the cells treated with RA or CD2398.
Activation o f AP-1 upon Treatment with CD437 In Vitro
Since antiproliferative effects of synthetic retinoids have recently been attributed to an anti-AP-1 activity (Fanjul et al., 1994; J.-Y. Chen et al., 1995; Li et al., 1996) , we studied the effects of CD437 on AP-1 activation. Using a vector containing five repeated AP-1 DNA-binding sites cloned in front of the CAT-reporter gene, we observed a 20-fold CAT induction after treatment with CD437 (5 x (Fig. 5) . In contrast, MeWo cells treated with CD2398 or RA showed no increase in AP-l-dependent CAT activity. Cotransfection of a full-length c-fos expression plasmid led to a 2.5-fold CAT induction (Fig. 5) , similarly to treatment of MeWo cells with PMA (100 ng/ml), a well-known activator of AP-1. The latter is in agreement with the observed moderate effect of PMA on growth of MeWo cells. Furthermore, electrophoretic mobility shift assays using an oligonucleotide containing an AP-1 DNA-binding motif as a probe confirmed upregulation of the AP-1 complex after exposure to CD437 (Fig. 6 A) . This protein-DNA interaction was specifically competed for by an excess of cold probe. In contrast, no such dramatic changes were observed in the presence of CD2398 and RA (5 x 10 -5 M, each) (Fig. 6 A) . Nuclear extracts of MeWo cells treated with these compounds showed only weak binding of the AP-1 sites. Since D N A binding of other unrelated transcription factors such as Nil-2 (not expressed) or Oct-1 (highly expressed) was not changed by the retinoid treatment (Fig. 6 B) , it can be assumed that CD437 specifically activates D N A binding of the AP-1 complex. AP-1 activation became visible as early as 3 h after exposure to CD437 and remained high for up to 48 h (Fig. 6 C) . Cells treated with RA or CD2398 also showed a slight increase in AP-1 DNA-binding activity ( Fig. 6 C) ; however, AP-1 complexes built upon RA or CD2398 treatment were not transcriptionally active as suggested by the activation of the CAT gene (Fig. 5 ) and the lack of growth inhibition (Fig. 2) . The AP-1 complex upon treatment with CD437 is formed by multiple members of the Fos and Jun protein family (Fig. 6 D) . Dissection of the AP-1 complex by gel retardation assays using nuclear extracts of melanoma cells and monospecific antibodies in a supershift assay revealed that (Fig. 6 D, upper) . In contrast with cell extracts prepared from R A -t r e a t e d cells, weak signals were obtained after coincubation with antibodies against Fra-1, c-Jun, and JunD (Fig. 6 D, lower) . U n d e r both conditions, A T F and CREB proteins do not participate in the AP-1 complex.
Northern blot analysis confirmed that m R N A expression of the protooncogenes c-los and c-jun, encoding members of the AP-1 complex, was concurrently upregulated after a 48-to 72-h exposure to CD437 (Fig. 7) , whereas CD2398 and R A had no such effect. Expression of p53 (Fig. 7) , which encodes a negative growth regulator and expression of the antiapoptotic gene bcl-2 (not shown), was not altered in M e W o cells upon treatment with any of the compounds (Fig. 7) . Taken together, gel shift assays demonstrated a CD437-induced increased AP-1 DNA-binding activity already 3 h after exposure to the retinoid (Fig. 6) , suggesting that posttranslational activation of the transcription factor is a primary event during CD437-induced apoptosis. As shown by Northern blot analysis (Fig. 7) , prolonged exposure to CD437 also stimulates expression of genes encoding components of the AP-1 complex.
Growth Inhibition of Human Melanoma Xenograft in Nude Mice with CD437 Treatment
To confirm the significance of the results obtained in vitro The original data from Northern blots were digitally processed using a HewlettPackard Scan Jet Ilcx.
for the in vivo situation, the human melanoma cell line MeWo was established to grow in nude mice. Preexisting tumors of 0.5 cm in diameter were treated for 3 wk with CD437 (10 and 30 mg/kg) in comparison to a vehicletreated group of control animals. Tumors in CD437-treated mice stopped growing, an effect that became already statistically significant (P < 0.01) at day 13, 3 d after first administration of CD437, and was maintained for more than 3 wk after discontinuation of treatment. No difference was observed depending on the route of administration (intratumorally or orally) (Fig. 8) . Intratumoral retinoid injections were chosen as one treatment arm, since no pharmacologic information regarding gastrointestinal resorption of CD437 upon oral application were available.
Further histologic analysis demonstrated marked c-fos m R N A levels at the tumor-stroma edge in CD437-treated tumors, as shown by in situ hybridization (Fig. 9 E) . TdTmediated deoxyuridine triphosphate-digoxigenin nick end labeling (TUNEL) staining, a procedure that labels free D N A terminal regions and is considered to be an indicator of cells undergoing apoptosis in situ (Fig. 9 D) , showed a staining pattern that colocalized to the area of high c-los expression in the CD437-treated tumors (Fig. 9 E) . Analysis of saline-treated control xenografts demonstrated no comparable c-fos expression or TUNEL staining (not shown).
Discussion
In the present study, we have identified the synthetic retinoid CD437 as being able to rapidly induce increased AP-1 DNA-binding resulting in an upregulation of the transcriptional activity of AP-1 and the induction of apoptotic cell death in human melanoma cells. The observed antiproliferative effect of CD437 is in agreement with the findings of others that RA and several synthetic retinoids may function as inductors of apoptosis in various cell lines (Alles and Sulik, 1990; Piacentini et al., 1991; Horie and Broxmeyer, 1995; Shao et al., 1995) . Antiproliferative effects of retinoids are presently believed to be mediated by an inhibition of AP-1 activity as a result of the competition for DNA-binding sites and of protein-protein interactions (Sch01e et at., 1990 (Sch01e et at., , 1991 Yang-Yen et al., 1991; Auwerx and Sassone-Corsi, 1992; Pfahl, 1993; Fanjul et al., 1994; J.-Y. Chen et al., 1995; Li et al., 1996) . The present report describes for the first time a retinoid-induced programmed cell death that is accompanied by an activation and upregulation of AP-1. It remains to be shown whether other syn- thetic retinoids with comparable activities exist, suggesting thus a new class of retinoids. Evidence for the occurrence of apoptotic cell death in human melanoma cells is provided by the demonstration of DNA fragmentation and by electron microscopical analysis of cell morphology. Only very recently, Shao and coworkers have shown that CD437 also induces apoptotic cell death in human breast cancer cells (Shao et al., 1995) . The present study provides additional data regarding the molecular mechanisms involved in this process. Thus, melanoma cell death upon treatment with CD437 in vitro was preceded by a substantial upregulation of the AP-1 complex (3 h after exposure) as demonstrated by electrophoretic mobility shift assays (Fig. 6) . Neither unrelated transcription factors such as Oct-1 or Nil-2 nor changes in the expression of p53 or bcl-2, which encode proteins known for their critical involvement in regulating apoptotic processes in various cell types, were modulated by CD437, suggesting that cell death was independent of these factors and that AP-1 activation upon CD437 treatment is a specific event. The data presented show that AP-1 activity is regulated at both a posttranslational and transcriptional level. Although it is not known which of the posttranslational mechanisms described (for review see Piechaczyk and Blanchard, 1994) are involved in upregulating AP-1 activity, modification of Fos and/or Jun protein activity seems to be an early event during CD437-induced programmed cell death. In contrast, transcriptional activation of the corresponding genes could be detected by Northern blot analysis only after prolonged treatment with CD437 (24-48 h).
An increase of c-los and c-jun expression preceding programmed cell death has been described in diverse systems such as growth factor deprivation of lymphoid cells (Colotta et al., 1992) , hormonal deprivation of rat prostate cells (Buttyan et al., 1988) , involution of the lactating mammary gland (Marti et al., 1994) , or the massive upregulation of the AP-1 complex in UV-damaged cells undergoing apoptosis (Devary et al., 1991; Engelberg et al., 1994; Schreiber et al., 1995) . Furthermore, neuronal apoptosis, which has recently been examined in great detail (Smeyne et al., 1993; Estus et al., 1994; S.C. Chen et al., 1995) , is characterized by a well-defined change in protooncogene expression with an increase of c-los and c-]un expression, whereas expression of other genes encoding AP-1 components such as fra-1 are downregulated (Estus et al., 1994) . At present, it seems safe to conclude from studies in transgenic mice that neuronal death as well as programmed cell death in other mesenchymal tissues such as chondrocytes and bone is preceded by a continuous c-los expression (Smeyne et al., 1993; Estus et al., 1994 ; S.C. . Since melanoma cells are also derived from neuroectoderm, it is reasonable to suggest that the cascade of gene expression leading to apoptotic cell death might be similar. Presently, it is not entirely clear whether the whole cascade known to occur during neuronal cell death also takes place during CD437-induced melanoma cell death.
In CD437-treated ceils studied here, c-Fos, c-Jun, and JunD are involved in AP-1 complex formation as shown by band shift analysis (Fig. 6 D) . In contrast, in cells exposed to RA, c-Jun, JunD, and Fra-1 were found to be part of AP-1, whereas c-Fos is missing. It is well known that by heterodimerization of Fos (c-Fos, FosB, and Fra-1) and Jun (c-Jun, JunB, and JunD) proteins and homodimerization of Jun proteins, >20 different AP-1 complexes can be formed. Studies with neuronal cells revealed that these complexes represent at least four groups with transactivational abilities ranging from high to very low (for review see Hughes and Dragunow, 1995) . c-Fos/c-Jun heterodimers belong to the group exhibiting the highest DNA-binding and transactivational potential, whereas AP-1 complexes built up by Fra-1 and different Jun proteins were much less active (Hughes and Dragunow, 1995) . In agreement with these earlier studies, we found that the highest AP-l-dependent CAT activity in cells treated with CD437 (Fig. 5 ) was most likely due to the formation of c-Fos/c-Jun heterodimers. In contrast, AP-1 constituents detected in RA-treated ceils (Fig. 6 D) only allow formation of AP-1 complexes with medium to very low activity (Hughes and Dragunow, 1995) . The finding that treatment of MeWo cells with different retinoids induces distinct AP-1 complexes is supported by our results of Northern blot analysis (Fig. 7) . Induction of c-fos mRNA could only be detected in CD437-treated cells.
While the components of the cellular signal transduction cascade responsible for the induction of apoptosis are presently unknown, it is very likely that alterations in gene expression resulting from changes in the composition of AP-1 are instrumental. Novel biochemical evidence indicates that the composition of AP-1 complexes and additional interacting proteins may predict subsequent gene expression and facilitate the switching between proliferation, terminal differentiation, and apoptosis (S.C. Hagmeyer et al., 1995; Schreiber et al., 1995; Kamei et al., 1996) .
Taken together, our data suggest that apoptosis in human melanoma cells may be similar to neuronal cell death and programmed cell death in other mesenchymal tissues, with an upregulation of c-los and c-jun expression preceding cell death. Furthermore, we describe CD437 as a member of a possible new class of synthetic retinoids that is capable of initiating the cell death program in human melanoma cells in vitro and that inhibits growth of xenografts in nude mice. Pharmacological induction of apoptosis in neoplastic cells is an aim of cancer therapy (Martin and Green, 1994) . Consequently, CD437 might be the first synthetic retinoid of a new generation of therapeutic agents inducing apoptosis via AP-1 activation and might therefore open up new opportunities for the treatment of metastatic melanoma.
